Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | BDKRB1 | P46663 | 11/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9530577 | 0.86 | KDM4E (0.57) | SLC6A3SLC6A4BDKRB1HIF1ASLC6A2 | |
| SCHEMBL5061628 | 0.86 | SLC6A3 (0.61) | SLC6A3SLC6A4BDKRB1SLC6A2LTB4R2 | |
| SCHEMBL29979869 | 0.82 | SLC6A3 (0.69) | SLC6A3SLC6A4BDKRB1SLC6A2LTB4R2 | |
| SCHEMBL3112718 | 0.82 | SLC6A3 (0.69) | SLC6A3SLC6A4BDKRB1SLC6A2LTB4R2 | |
| SCHEMBL14326964 | 0.82 | SLC6A3 (0.69) | SLC6A3SLC6A4BDKRB1SLC6A2LTB4R2 | |
| SCHEMBL20183559 | 0.82 | SLC6A3 (0.60) | SLC6A3SLC6A4BDKRB1SLC6A2 | |
| SCHEMBL7175089 | 0.81 | SLC6A3 (0.63) | SLC6A3SLC6A4BDKRB1SLC6A2LTB4R2 | |
| SCHEMBL17158407 | 0.81 | CA1 (0.80) | CA1CA2HIF1A | |
| SCHEMBL20183802 | 0.81 | CA1 (0.80) | CA1CA2HIF1A | |
| SCHEMBL2782748 | 0.81 | CHRNB2 (0.59) | SLC6A3SLC6A4BDKRB1LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522873-B2 | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-12-20 | — | — | US | disclosed |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | disclosed |
| US-8673889-B2 | BLT2-mediated disease, BLT2 binding agent and the compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2172222-A2 | Novel BLT2-mediated disease, BLT2-binding agent and compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1745800-A1 | NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132574-A1 | Novel Blt2-Mediated Disease, Blt2 Binding Agent And the Compound | MALT1, SLC10A2, LCP2 | SLC6A3 134/4885SLC6A4 305/4885CA1 3740/4885 |
| US-20150291509-A1 | NOVEL BIPHENYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY DISEASES OR AUTOIMMUNE DISEASES COMPRISING THE SAME AS ACTIVE INGREDIENT | CD47, MSR1, CD14 | SLC6A3 366/4885SLC6A4 1163/4885CA1 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.